BridgeBio Pharma News

Express News | BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe

Breakings08:12

Express News | BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement

Breakings08:12

Express News | BridgeBio Pharma Inc - FDA Approves Attruby for Treatment of Attr-Cm

Breakings08:11

Express News | Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients

Breakings08:11

Trading Halt: Halted at 4:08:53 P.m. ET - Trading Halt: Halt News Pending

Benzinga05:08

Things Look Grim For BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Today's Downgrade

Simply Wall StNov 22 18:43

Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?

Yahoo FinanceNov 22 06:43

J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $40

Futu NewsNov 21 20:34 · Ratings

Express News | BridgeBio Pharma Inc : JP Morgan Cuts Target Price to $40 From $43

BreakingsNov 20 13:58

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

BenzingaNov 20 03:44

Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45

Futu NewsNov 19 21:32 · Ratings

BridgeBio Pharma (BBIO) Gets a Buy From Scotiabank

TipRanksNov 19 20:55 · Ratings

Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45

Futu NewsNov 19 19:32 · Ratings

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

Yahoo FinanceNov 19 18:57

Promising Phase 3 Results for Acoramidis Support Buy Rating for BridgeBio Pharma Despite Study Limitations

TipRanksNov 19 18:46 · Ratings

Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating

Futu NewsNov 19 16:36 · Ratings

BridgeBio Pharma Says The Continued Curve Separation Of The Composite Endpoint Of ACM And Recurrent Cardiovascular-Related Hospitalizations Emphasizes The Importance Of Early Intervention Resulting In Early And Sustained Clinical Benefits, With...

BenzingaNov 19 00:19

BridgeBio Pharma Presented Initial Outcomes From The ATTRibute-CM Open-label Extension Study Of Acoramidis In ATTR-CM At The AHA Scientific Sessions; Acoramidis Demonstrated The Earliest Known Time To Separation In Cardiovascular Outcomes In The...

BenzingaNov 19 00:17

Express News | BridgeBio Pharma Inc - Acoramidis Well Tolerated With No New Safety Signals in Long-Term Evaluation

BreakingsNov 19 00:16

Express News | Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BreakingsNov 19 00:15